IBRX261113C00013000
IBRX Nov 13 2026 13.00 Call
optionOPRA
EODOct 14, 2026
0.43USD-18.868%(-0.10)88Vol120OI
Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
13
Expiration
Nov 13, 2026
DTE
24d
Moneyness
OTM
Intrinsic
$0.00
IBRX 13 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $0.10 | -73.68% | 20 | 41 |
| Oct 30, 2026 | 10d | $0.15 | -21.05% | 4 | 33 |
| Nov 6, 2026 | 17d | $0.43 | +22.86% | 7 | 33 |
| Nov 13, 2026 | 24d | $0.43 | -18.87% | 88 | 120 |
| Nov 20, 2026 | 31d | $0.25 | -39.02% | 2 | 1,184 |
| Nov 27, 2026 | 38d | — | — | 0 | 0 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Jan 15, 2027 | 87d | $0.89 | -33.58% | 66 | 898 |
| Mar 19, 2027 | 150d | $2.00 | +42.86% | 5 | 23 |
| Apr 16, 2027 | 178d | $2.11 | +24.12% | 40 | 44 |
| May 21, 2027 | 213d | $1.15 | +0.00% | 1 | 1 |
IBRX Nearby Strikes · Nov 13, 2026
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.